Small-cell lung cancer (SCLC) encounters up 15% of all lung cancers, and is characterized
by a high rate of proliferation, a tendency for early metastasis and generally poor prognosis …

Small-cell lung cancer (SCLC) accounts for 13–15% of all new lung cancer cases in the US.
The tumor has a tendency to disseminate early resulting in 80–85% of patients being …

Purpose Irinotecan plus cisplatin (IP) improved survival over etoposide plus cisplatin (EP) in
Japanese patients with extensive-stage small-cell lung cancer (E-SCLC). To confirm those …

Small cell lung cancer TP53 mutations lead to expression of tumor antigens that elicits
specific cytotoxic T-cell immune responses. In this phase II study, dendritic cells transfected …

Purpose Elevated plasma fibrinogen and D-dimer levels indicate activation of hemostasis
and fibrinolysis, and this activation is required for tumor angiogenesis, metastasis, and …

Chemotherapy plays a significant role both as primary and as supportive care for lung
cancer treatment. The majority of currently available anticancer agents are administrated …

Background This study evaluated the efficacy and safety of irinotecan/cisplatin (IP) and
etoposide/cisplatin (EP) in extensive‐stage small cell lung cancer (ES‐SCLC) and the …

Abstract BACKGROUND: Southwest Oncology Group 0124 was a large North American
phase 3 trial that failed to confirm a survival benefit for cisplatin/irinotecan over …

Histone deacetylase (HDAC) inhibitors, including MGCD0103 and vorinostat, have led to
tumor growth inhibition and apoptosis in vivo. However, with limited single-agent activity …

Purpose: The aim of this study was to evaluate the cost-effectiveness of a recently approved
first-line therapy (adebrelimab plus chemotherapy vs. chemotherapy alone) for patients with …